Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics

Journal of Clinical Pharmacology

Volumn 44, Issue 11, 2004, Pages 1260-1272

  Jiang, Hao ^a,c   Lu, Jing ^b   Jiang, Ji ^a   Hu, Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 fluorouracil; Dihydrouracil uracil ratio; Floxuridine; Gestational trophoblastic tumor; Individual dose adjustment

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; DIHYROPYRIMIDINE DEHYDROGENASE; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHORIOCARCINOMA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MUCOSA INFLAMMATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; SINGLE DRUG DOSE; TROPHOBLASTIC TUMOR; VOMITING;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHORIONIC GONADOTROPIN; FEMALE; FLOXURIDINE; FLUOROURACIL; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; LEUKOCYTE COUNT; METABOLIC CLEARANCE RATE; NEUTROPHILS; PRODRUGS; PROSPECTIVE STUDIES; URACIL;

EID: 6344247602     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268911     Document Type: Article

References (41)

1. Sharma S, Jagdev S, Coleman RE, et al. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer. 1999;81:1037-1041.
2. Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol. 1995;172:574-579.
3. Lan Z, Hongzhao S, Xiuyu Y, Yang X. Pregnancy outcomes of patients who conceived within 1 year after chemotherapy for gestational trophoblastic tumor: a clinical report of 22 patients. Gynecol Oncol. 2001;83:146-148.
4. Pan L, Yang X, Song H. Cardiotoxicity of 5-fluorouracil. Zhonghua Fu Chan Ke Za Zhi. 1996;31:86-89.
5. Song HZ, Dong SY, Yang XY. Long-term follow up of pregnancy outcome after successful chemotherapy for gestational trophoblastic tumor. Chinese J Obstet. 1987;22:339-345.
6. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215-237.
7. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int. 2002;19:177-189.
8. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12:2248-2253.
9. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53:5433-5438.
10. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50:197-201.
11. Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 1994;4:301-306.
12. Gardiner SJ, Begg EJ, Robinson BA. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React Toxicol Rev. 2002;21:1-16.
13. Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-4712.
14. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul. 2001;41:151-157.
15. Usuki H, Ishimura K, Yachida S, et al. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. Gastric Cancer. 2003;6(suppl 1):66-70.
16. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol. 1999;17:1105-1110.
17. Fleming RA, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-2902.
18. Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985;313:245-249.
19. Bi D, Andersom LW, Shapiro J, et al. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatogr B. 2000;738:249-258.
20. Morimoto S, Mishima H, Tsujinaka T, et al. Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative. Can To Kagaku Ryoho. 2003;30:89-94.
21. Foth H, Hellkamp J, Kunellis EM, Kahl GF. Pulmonary elimination and metabolism of 5-fluoro-2′-deoxyuridine in isolated perfused rat lung and lung slices. Drug Metab Dispos. 1990;18:1011-1017.
22. Jiang H, Lu J, Ji J. Orcadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol. 2004;141:617-624.
23. Cole LA, Sutton JM. HCG tests in the management of gestational trophoblastic diseases. Clin Obstet Gynecol. 2003;46:523-540.
24. Okamoto T, Matsuo K, Niu R, Osawa M, Suzuki H. Human chorionic gonadotropin (hCG) beta-core fragment is produced by degradation of hCG or free hCG beta in gestational trophoblastic tumors: a possible marker for early detection of persistent postmolar gestational trophoblastic disease. J Endocrinol. 2001;171:435-443.
25. Evans BD, Harvey VJ, Knox BS, Duff G. HCG-choosing the best assay to monitor gestational trophoblastic disease and other germ cell tumours. N Z Med J. 1993;106:261-266.
26. Song HZ, Wu PC, Tang MY. Diagnosis and Treatment in Gestational Trophoblastic Tumor. Beijing: People Medical Publishers, 1981;1-19.
27. Jiang H, Jiang J, Hu P. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;769:169-176.
28. Schmiegelow K, Bretton-Meyer U. 6-Mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia. 2001;15:74-79.
29. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18:521-529.
30. Mungan T, Kuscu E, Ugur M, et al. Screening of persistent trophoblastic disease with various serum markers. Eur J Gynaecol Oncol. 1998;19:495-497.
31. Bakri Y, al-Hawashim N, Berkowitz R. CSF/serum beta-hCG ratio in patients with brain metastases of gestational trophoblastic tumor. J Reprod Med. 2000;45:94-96.
32. Assersohn L, Norman AR, Cunningham D, et al. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer. 2003;39:1121-1128.
33. Tebbutt NC, Norman A, Cunningham D, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002;13:1568-1575.
34. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem. 2003;40:41-45.
35. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 2000;61:199-203.
36. Horiguchi J, Yoshida T, Koibuchi Y, et al. DPD activity and immunohistochemical DPD expression in human breast cancer. Oncol Rep. 2004;11:65-72.
37. Kosaka A, Mori K, Shikata A. Significance of tissue PyNPase, TS, and DPD activities in breast cancer. Gan To Kagaku Ryoho. 2002;29:1395-1401.
38. Hakamada Y, Arima M, Misaka T, et al. Significance of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) activity in breast cancer tissue. Gan To Kagaku Ryoho. 2000;27:1003-1010.
39. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Huntingt) 1998;12(suppl 7):23-27.
40. Shibamoto Y, Mimasu Y, Tachi Y, et al. Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrugs. J Chemother. 2002;14:390-396.
41. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22:648-657.